Logo image of EVO

EVOTEC SE - SPON ADR (EVO) Stock Fundamental Analysis

USA - NASDAQ:EVO - US30050E1055 - ADR

4.04 USD
+0.11 (+2.8%)
Last: 10/23/2025, 4:30:02 PM
4.04 USD
0 (0%)
After Hours: 10/23/2025, 4:30:02 PM
Fundamental Rating

2

Taking everything into account, EVO scores 2 out of 10 in our fundamental rating. EVO was compared to 57 industry peers in the Life Sciences Tools & Services industry. EVO may be in some trouble as it scores bad on both profitability and health. EVO is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

EVO had negative earnings in the past year.
In the past year EVO had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: EVO reported negative net income in multiple years.
In the past 5 years EVO always reported a positive cash flow from operatings.
EVO Yearly Net Income VS EBIT VS OCF VS FCFEVO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

1.2 Ratios

EVO has a Return On Assets (-8.60%) which is in line with its industry peers.
The Return On Equity of EVO (-18.39%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -8.6%
ROE -18.39%
ROIC N/A
ROA(3y)-7.25%
ROA(5y)-2.34%
ROE(3y)-14.29%
ROE(5y)-5.27%
ROIC(3y)N/A
ROIC(5y)N/A
EVO Yearly ROA, ROE, ROICEVO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20

1.3 Margins

EVO has a worse Gross Margin (12.89%) than 84.21% of its industry peers.
EVO's Gross Margin has declined in the last couple of years.
EVO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 12.89%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-16.23%
GM growth 5Y-13.5%
EVO Yearly Profit, Operating, Gross MarginsEVO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20

More info and screens

3

2. Health

2.1 Basic Checks

EVO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for EVO has been increased compared to 1 year ago.
The number of shares outstanding for EVO has been increased compared to 5 years ago.
The debt/assets ratio for EVO has been reduced compared to a year ago.
EVO Yearly Shares OutstandingEVO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
EVO Yearly Total Debt VS Total AssetsEVO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

Based on the Altman-Z score of 0.59, we must say that EVO is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.59, EVO is doing worse than 66.67% of the companies in the same industry.
The Debt to FCF ratio of EVO is 37.11, which is on the high side as it means it would take EVO, 37.11 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 37.11, EVO is in line with its industry, outperforming 52.63% of the companies in the same industry.
EVO has a Debt/Equity ratio of 0.42. This is a healthy value indicating a solid balance between debt and equity.
EVO has a Debt to Equity ratio (0.42) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.42
Debt/FCF 37.11
Altman-Z 0.59
ROIC/WACCN/A
WACC7.15%
EVO Yearly LT Debt VS Equity VS FCFEVO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

A Current Ratio of 1.58 indicates that EVO should not have too much problems paying its short term obligations.
The Current ratio of EVO (1.58) is worse than 70.18% of its industry peers.
EVO has a Quick Ratio of 1.49. This is a normal value and indicates that EVO is financially healthy and should not expect problems in meeting its short term obligations.
EVO's Quick ratio of 1.49 is in line compared to the rest of the industry. EVO outperforms 42.11% of its industry peers.
Industry RankSector Rank
Current Ratio 1.58
Quick Ratio 1.49
EVO Yearly Current Assets VS Current LiabilitesEVO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

3

3. Growth

3.1 Past

The earnings per share for EVO have decreased strongly by -136.17% in the last year.
EVO shows a decrease in Revenue. In the last year, the revenue decreased by -1.41%.
Measured over the past years, EVO shows a quite strong growth in Revenue. The Revenue has been growing by 12.29% on average per year.
EPS 1Y (TTM)-136.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.56%
Revenue 1Y (TTM)-1.41%
Revenue growth 3Y8.85%
Revenue growth 5Y12.29%
Sales Q2Q%-5.98%

3.2 Future

EVO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.70% yearly.
EVO is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.19% yearly.
EPS Next Y57.39%
EPS Next 2Y35.45%
EPS Next 3Y27.47%
EPS Next 5Y19.7%
Revenue Next Year-2.27%
Revenue Next 2Y4.05%
Revenue Next 3Y6.5%
Revenue Next 5Y7.19%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
EVO Yearly Revenue VS EstimatesEVO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
EVO Yearly EPS VS EstimatesEVO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 0.2 -0.2 0.4 -0.4 0.6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

EVO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year EVO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EVO Price Earnings VS Forward Price EarningsEVO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

EVO's Enterprise Value to EBITDA ratio is in line with the industry average.
EVO's Price/Free Cash Flow is on the same level as the industry average.
Industry RankSector Rank
P/FCF 99.43
EV/EBITDA 91.06
EVO Per share dataEVO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

EVO's earnings are expected to grow with 27.47% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.45%
EPS Next 3Y27.47%

More info and screens

0

5. Dividend

5.1 Amount

EVO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EVOTEC SE - SPON ADR

NASDAQ:EVO (10/23/2025, 4:30:02 PM)

After market: 4.04 0 (0%)

4.04

+0.11 (+2.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)08-13 2025-08-13/bmo
Earnings (Next)11-05 2025-11-05/bmo
Inst Owners60.42%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner Change0%
Market Cap1.43B
Revenue(TTM)777.33M
Net Income(TTM)-155528000
Analysts78.46
Price Target5.54 (37.13%)
Short Float %0.21%
Short Ratio11.04
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-4.94%
Min Revenue beat(2)-5.1%
Max Revenue beat(2)-4.77%
Revenue beat(4)0
Avg Revenue beat(4)-4.23%
Min Revenue beat(4)-6.12%
Max Revenue beat(4)-0.93%
Revenue beat(8)2
Avg Revenue beat(8)-0.61%
Revenue beat(12)4
Avg Revenue beat(12)1.62%
Revenue beat(16)8
Avg Revenue beat(16)3.57%
PT rev (1m)-1.92%
PT rev (3m)-7.18%
EPS NQ rev (1m)0%
EPS NQ rev (3m)23.05%
EPS NY rev (1m)-0.44%
EPS NY rev (3m)-63.97%
Revenue NQ rev (1m)-6.77%
Revenue NQ rev (3m)-14.44%
Revenue NY rev (1m)-1.07%
Revenue NY rev (3m)-9.78%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.59
P/FCF 99.43
P/OCF 11.1
P/B 1.46
P/tB 2.29
EV/EBITDA 91.06
EPS(TTM)-0.64
EYN/A
EPS(NY)-0.11
Fwd EYN/A
FCF(TTM)0.04
FCFY1.01%
OCF(TTM)0.36
OCFY9.01%
SpS2.54
BVpS2.76
TBVpS1.77
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -8.6%
ROE -18.39%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 12.89%
FCFM 1.6%
ROA(3y)-7.25%
ROA(5y)-2.34%
ROE(3y)-14.29%
ROE(5y)-5.27%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-16.23%
GM growth 5Y-13.5%
F-Score4
Asset Turnover0.43
Health
Industry RankSector Rank
Debt/Equity 0.42
Debt/FCF 37.11
Debt/EBITDA 26.48
Cap/Depr 97.54%
Cap/Sales 12.75%
Interest Coverage N/A
Cash Conversion 831.71%
Profit Quality N/A
Current Ratio 1.58
Quick Ratio 1.49
Altman-Z 0.59
F-Score4
WACC7.15%
ROIC/WACCN/A
Cap/Depr(3y)186.39%
Cap/Depr(5y)182.37%
Cap/Sales(3y)22.79%
Cap/Sales(5y)21.48%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-136.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.56%
EPS Next Y57.39%
EPS Next 2Y35.45%
EPS Next 3Y27.47%
EPS Next 5Y19.7%
Revenue 1Y (TTM)-1.41%
Revenue growth 3Y8.85%
Revenue growth 5Y12.29%
Sales Q2Q%-5.98%
Revenue Next Year-2.27%
Revenue Next 2Y4.05%
Revenue Next 3Y6.5%
Revenue Next 5Y7.19%
EBIT growth 1Y-20.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year132.47%
EBIT Next 3Y50.57%
EBIT Next 5Y33.8%
FCF growth 1Y105.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y359%
OCF growth 3Y-46.98%
OCF growth 5Y-15.47%